Instrument Inactif

Communiqués Diffusion Pharmaceuticals Inc Other OTC

Actions

US76132G1058

Cours en clôture Other OTC Autres places de cotation
- ^USD	-

16/08/23	EIP Pharma, Inc. a conclu l'acquisition de Diffusion Pharmaceuticals Inc. (NasdaqCM:DFFN) dans le cadre d'une opération de fusion inversée.	CI
15/08/23	Les actionnaires de Diffusion Pharmaceuticals approuvent la fusion avec EIP Pharma ; les actions montent	MT

Communiqués

21/12/23	Diffusion Pharma : CervoMed Corporate Presentation December 2023	PU
15/08/23	Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma	AQ
14/08/23	Diffusion Pharmaceuticals : EIP Pharma Announces First Patient Dosed in RewinD-LB Phase 2b Clinical Trial Evaluating Neflamapimod in Dementia with Lewy Bodies - Form 8-K	PU
09/08/23	Diffusion Pharmaceuticals : UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION - Form 8-K	PU
03/08/23	Diffusion Pharmaceuticals : EIP Pharma to Present at Canaccord Genuity 43rd Annual Growth Conference - Form 8-K	PU
21/06/23	DIFFUSION PHARMACEUTICALS INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
15/05/23	DIFFUSION PHARMACEUTICALS INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
11/05/23	Diffusion Pharmaceuticals : EIP Pharma to Present at JMP Securities Life Sciences Conference - Form 8-K	PU
01/04/23	DIFFUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Diffusion Pharmaceuticals Inc. - DFFN	BU
30/03/23	Diffusion Pharmaceuticals : FORM OF PARENT STOCKHOLDER SUPPORT AGREEMENT - Form 8-K	PU
30/03/23	DIFFUSION PHARMACEUTICALS INC. : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
30/03/23	EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative Diseases	AQ
24/03/23	DIFFUSION PHARMACEUTICALS INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ
16/02/23	DIFFUSION PHARMACEUTICALS INC. : Termination of a Material Definitive Agreement, Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
30/12/22	DIFFUSION PHARMACEUTICALS INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	AQ
16/12/22	DIFFUSION PHARMACEUTICALS INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
06/12/22	DIFFUSION PHARMACEUTICALS INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
17/11/22	LifeSci Special Opportunities Responds to Recent Press Release Issued by Diffusion Pharmaceuticals	AQ
14/11/22	DIFFUSION PHARMACEUTICALS INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
14/11/22	Diffusion Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update	AQ
14/11/22	DIFFUSION PHARMACEUTICALS INC. : Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
10/11/22	DIFFUSION PHARMACEUTICALS INC. : Shareholder Director Nominations, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
27/10/22	DIFFUSION PHARMACEUTICALS INC. : Shareholder Director Nominations, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
26/10/22	Diffusion Pharmaceuticals : DFFN Corporate Presentation - 3Q 2022 NC	PU
25/10/22	Diffusion Pharmaceuticals Announces Strategic Review Process to Evaluate Value-Enhancing Alternatives including Opportunities to Better Leverage TSC	AQ